Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Karyopharm Therapeutics Inc. has received a consensus recommendation of "Moderate Buy" from five research firms, with an average 1-year price target of $34.00.
• Recent brokerage ratings have seen a mix of downgrades and changes, with Robert W. Baird lowering their price target from $42.00 to $25.00 and HC Wainwright changing their rating from "buy" to "neutral".
• Institutional investors hold 66.44% of Karyopharm's shares, with Adage Capital Partners increasing their stake by 46.3% in the fourth quarter.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $34.00.

A number of brokerages have commented on KPTI. Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. HC Wainwright cut Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 16th. Wall Street Zen cut Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. Royal Bank Of Canada reduced their price objective on Karyopharm Therapeutics from $34.00 to $33.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, Barclays boosted their price objective on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. lifted its stake in shares of Karyopharm Therapeutics by 46.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company's stock worth $4,274,000 after acquiring an additional 2,000,000 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Karyopharm Therapeutics by 15.3% in the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company's stock worth $1,633,000 after acquiring an additional 319,187 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company's stock worth $942,000 after acquiring an additional 36,922 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock worth $506,000 after acquiring an additional 543,556 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Karyopharm Therapeutics by 23.5% in the fourth quarter. Northern Trust Corp now owns 283,729 shares of the company's stock worth $192,000 after acquiring an additional 54,061 shares in the last quarter. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Trading Up 4.5%

Shares of Karyopharm Therapeutics stock opened at $6.50 on Thursday. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $16.95. The stock has a market capitalization of $56.36 million, a P/E ratio of -0.45 and a beta of 0.28. The business's fifty day moving average price is $4.46 and its 200 day moving average price is $5.54.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The business had revenue of $37.93 million during the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.